Adnan Ali

Adnan Ali

Auto-generated profile, based on publicly available information

Adnan Ali

Clinical Hub for Interventional Research, John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory, Australia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Annals of Oncology
Verified
Journal Article
Open access
NCNoel Clarke
Noel Clarke
AAA. Ali
A. Ali
FIFiona Ingleby
Fiona Ingleby
AHA. Hoyle
A. Hoyle
CAC.L. Amos
C.L. Amos
NJN.D. James
N.D. James
STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report on long-term outcomes stratified by metastatic burden for M1 patients. We randomly allocated patients in 2 : 1 ratio to standard-of-care (SOC; control group) or SOC + docetaxel. Metastatic disease burden was categorised using retrospectively-collected baseline staging scans where available. Analysis used Cox regression models, adjusted for stratification factors, with emphasis on restricted mean survival time where hazards were non-proportional. Between 05 October 2005 and 31 March 2013, 1086 M1 patients were randomised to receive SOC (n = 724) or SOC + docetaxel (n = 362). Metastatic burden was assessable for 830/1086 (76%) patients; 362 (44%) had low and 468 (56%) high metastatic burden. Median follow-up was 78.2 months. There were 494 deaths on SOC (41% more than the previous report). There was good evidence of benefit of docetaxel over SOC on OS (HR = 0.81, 95% CI 0.69-0.95, P = 0.009) with no evidence of heterogeneity of docetaxel effect between metastatic burden sub-groups (interaction P = 0.827). Analysis of other outcomes found evidence of benefit for docetaxel over SOC in failure-free survival (HR = 0.66, 95% CI 0.57-0.76, P < 0.001) and progression-free survival (HR = 0.69, 95% CI 0.59-0.81, P < 0.001) with no evidence of heterogeneity of docetaxel effect between metastatic burden sub-groups (interaction P > 0.5 in each case). There was no evidence that docetaxel resulted in late toxicity compared with SOC: after 1 year, G3-5 toxicity was reported for 28% SOC and 27% docetaxel (in patients still on follow-up at 1 year without prior progression). The clinically significant benefit in survival for upfront docetaxel persists at longer follow-up, with no evidence that benefit differed by metastatic burden. We advocate that upfront docetaxel is considered for metastatic hormone naïve prostate cancer patients regardless of metastatic burden.

16 May 2022 in International Journal of Cancer
Verified
Journal Article
Open access
NJNicholas D. James
Nicholas D. James
NCNoel Clarke
Noel Clarke
ACAdrian Cook
Adrian Cook
AAAdnan Ali
Adnan Ali
AHAlex P. Hoyle
Alex P. Hoyle
FGfor the STAMPEDE Trials Collaborative Group
for the STAMPEDE Trials Collaborative Group
Abiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in STAMPEDE, a multiarm, multistage platform trial in men starting long‐term hormone therapy for prostate cancer. This long‐term analysis in metastatic patients was planned for 3 years after the first results. Standard‐of‐care (SOC) was androgen deprivation therapy. The comparison randomised patients 1:1 to SOC‐alone with or without daily abiraterone acetate 1000 mg + prednisolone 5 mg (SOC + AAP), continued until disease progression. The primary outcome measure was overall survival. Metastatic disease risk group was classified retrospectively using baseline CT and bone scans by central radiological review and pathology reports. Analyses used Cox proportional hazards and flexible parametric models, accounting for baseline stratification factors. One thousand and three patients were contemporaneously randomised (November 2011 to January 2014): median age 67 years; 94% newly‐diagnosed; metastatic disease risk group: 48% high, 44% low, 8% unassessable; median PSA 97 ng/mL. At 6.1 years median follow‐up, 329 SOC‐alone deaths (118 low‐risk, 178 high‐risk) and 244 SOC + AAP deaths (75 low‐risk, 145 high‐risk) were reported. Adjusted HR = 0.60 (95% CI: 0.50‐0.71; P = 0.31 × 10−9) favoured SOC + AAP, with 5‐years survival improved from 41% SOC‐alone to 60% SOC + AAP. This was similar in low‐risk (HR = 0.55; 95% CI: 0.41‐0.76) and high‐risk (HR = 0.54; 95% CI: 0.43‐0.69) patients. Median and current maximum time on SOC + AAP was 2.4 and 8.1 years. Toxicity at 4 years postrandomisation was similar, with 16% patients in each group reporting grade 3 or higher toxicity. A sustained and substantial improvement in overall survival of all metastatic prostate cancer patients was achieved with SOC + abiraterone acetate + prednisolone, irrespective of metastatic disease risk group.

17 January 2022 in Oncogene
Verified
Journal Article
Open access
PDF file
ACA. Cannistraci
A. Cannistraci
PHP. Hascoet
P. Hascoet
AAA. Ali
A. Ali
PMP. Mundra
P. Mundra
NCN. W. Clarke
N. W. Clarke
RMR. Marais
R. Marais
Prostate cancer (PCa) is the fifth leading cause of cancer related deaths worldwide, in part due to a lack of molecular stratification tools that can distinguish primary tumours that will remain indolent from those that will metastasise. Amongst potential molecular biomarkers, microRNAs (miRs) have attracted particular interest because of their high stability in body fluids and fixed tissues. These small non-coding RNAs modulate several physiological and pathological processes, including cancer progression. Herein we explore the prognostic potential and the functional role of miRs in localised PCa and their relation to nodal metastasis. We define a 7-miR signature that is associated with poor survival independently of age, Gleason score, pathological T state, N stage and surgical margin status and that is also prognostic for disease-free survival in patients with intermediate-risk localised disease. Within our 7-miR signature, we show that miR-378a-3p (hereafter miR-378a) levels are low in primary tumours compared to benign prostate tissue, and also lower in Gleason score 8–9 compared to Gleason 6–7 PCa. We demonstrate that miR-378a impairs glucose metabolism and reduces proliferation in PCa cells through independent mechanisms, and we identify glucose transporter 1 (GLUT1) messenger RNA as a direct target of miR-378a. We show that GLUT1 inhibition hampers glycolysis, leading to cell death. Our data provides a rational for a new PCa stratification strategy based on miR expression, and it reveals that miR-378a and GLUT1 are potential therapeutic targets in highly aggressive glycolytic PCa.

19 May 2018 in BJU International
Verified
Journal Article
Closed access
PDF file
AAAdnan Ali
Adnan Ali
AHAlexander Hoyle
Alexander Hoyle
HMHitesh Mistry
Hitesh Mistry
NCNoel Clarke
Noel Clarke

5 August 2025 in Annals of Emergency Medicine
Verified
Journal Article
Open access
AAAdnan Ali
Adnan Ali
RGRussell L. Gruen
Russell L. Gruen
SBStephen A. Bernard
Stephen A. Bernard
BBBrian Burns
Brian Burns
AFAndrew B. Forbes
Andrew B. Forbes
BMBiswadev Mitra
Biswadev Mitra
Trauma resuscitation guidelines across the world have incorporated the administration of tranexamic acid (TXA) within 3 hours of injury. The 3-hour window was deduced from the Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage (CRASH-2) trial and has not been replicated. The aim of this study was to determine whether death within 28 days after trauma varied according to time from injury to the first TXA dose and, if so, precisely determine the therapeutic window. This was an exploratory analysis of the Prehospital Tranexamic Acid for Severe Trauma (PATCH-Trauma) trial, which enrolled adults with major trauma and suspected trauma-induced coagulopathy. Eligible patients were randomized to receive either TXA (administered intravenously as a bolus dose of 1 g before hospital admission, followed by a 1 g infusion over a period of 8 hours after arrival at the hospital) or matched placebo. In this analysis, we examined the effect of time from injury to first treatment dose on death within 28 days utilizing a continuous scale with linear, first-degree fractional polynomial, and second-degree fractional polynomial functions of time from injury to first treatment dose. Further log-binomial regression analyses were performed in subgroups based on the information obtained from the previous step. The intention-to-treat study cohort comprised 1,287 patients, of which 635 had been allocated to the placebo arm and 652 to the TXA arm. The median time from injury to first treatment dose was 79 (interquartile range [IQR] 55 to 112) minutes. Risk of death within 28 days increased as the time to first dose of treatment increased, with benefit most pronounced up to 90 minutes. Beyond 90 minutes, the upper 95% confidence interval (CI) crossed the line of equivalence (risk ratio, 1). Administration of TXA within 90 minutes significantly reduced the risk of death within 28 days (67/393 [17%] in the TXA group versus 91/363 [25%] in placebo group; adjusted risk ratio 0.64, 95% CI 0.50 to 0.82), whereas administration beyond 90 minutes did not decrease mortality at 28 days (adjusted risk ratio 1.04, 95% CI 0.74 to 1.47). The optimal therapeutic window for TXA after trauma may be within 90 minutes.

1 August 2020 in European Urology Oncology
Verified
Journal Article
Open access
AAAdnan Ali
Adnan Ali
AHAlex P. Hoyle
Alex P. Hoyle
CPChristopher C. Parker
Christopher C. Parker
CBChristopher D. Brawley
Christopher D. Brawley
ACAdrian Cook
Adrian Cook
NCNoel Clarke
Noel Clarke
Prostate radiotherapy (RT) is a first-line option for newly diagnosed men with low-burden metastatic prostate cancer. The current criterion to define this clinical state is based on manual bone metastasis counts, but enumeration of bone metastases is limited by interobserver variations, and it does not account for metastasis volume or lesional coalescence. The automated bone scan index (aBSI) is a quantitative method of evaluating bone metastatic burden in a standardised and reproducible manner. To evaluate whether aBSI has utility as a predictive imaging biomarker to define a newly diagnosed metastatic prostate cancer population that might benefit from the addition of prostate RT to standard of care (SOC) systemic therapy. This is an exploratory analysis of men with newly diagnosed metastatic prostate cancer randomised in a 1:1 ratio to either SOC or SOC + prostate RT within the STAMPEDE "M1|RT comparison". The SOC was lifelong androgen deprivation therapy, with up-front docetaxel permitted from December 2015. Men allocated RT received either a daily or a weekly schedule that was nominated before randomisation. Baseline bone scans were evaluated retrospectively to calculate aBSI. We used overall (OS) and failure-free (FFS) survival as the end points. Treatment-aBSI interaction was evaluated using the multivariable fractional polynomial interaction (MFPI) and subpopulation treatment effect pattern plot. Further analysis was done in aBSI quartiles using Cox regression models adjusted for stratification factors. Baseline bone scans for 660 (SOC: 323 and SOC + RT: 337) of 2061 men randomised within the "M1|RT comparison" met the software requirements for aBSI calculation. The median age was 68 yr, median PSA was 100 ng/mL, median aBSI was 0.9, and median follow-up was 39 mo. Baseline patient characteristics including aBSI were balanced between the treatment groups. Using the MFPI procedure, there was evidence of aBSI-treatment interaction for OS (p = 0.04, MFPI procedure) and FFS (p < 0.01, MFPI procedure). Graphical evaluation of estimated treatment effect plots showed that the OS and FFS benefit from prostate RT was greatest in patients with a low aBSI. Further analysis in quartiles based on aBSI supported this finding. A low automated bone scan index is predictive of survival benefit associated with prostate RT in men with newly diagnosed metastatic prostate cancer. The widely used bone scan can be evaluated using an automated technique to potentially select men with newly diagnosed metastatic prostate cancer who might benefit from prostate radiotherapy.